In the latest session, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $3.98 down -1.49% from its previous closing price of $4.04. In other words, the price has decreased by $-0.0600 from its previous closing price. On the day, 826703 shares were traded. ABCL stock price reached its highest trading level at $4.0300 during the session, while it also had its lowest trading level at $3.9300.
For a deeper understanding of AbCellera Biologics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.33 and its Current Ratio is at 8.34. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 26 when Thermopylae Holdings Ltd. bought 153,000 shares for $6.52 per share. The transaction valued at 997,728 led to the insider holds 56,012,493 shares of the business.
Booth Andrew bought 14,500 shares of ABCL for $99,325 on May 26. The Chief Financial Officer now owns 153,000 shares after completing the transaction at $6.85 per share. On Dec 16, another insider, Thermopylae Holdings Ltd., who serves as the 10% Owner of the company, bought 85,102 shares for $10.10 each. As a result, the insider paid 859,249 and bolstered with 55,859,493 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1.15B and an Enterprise Value of 449.79M. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.92 while its Price-to-Book (P/B) ratio in mrq is 0.97. Its current Enterprise Value per Revenue stands at 8.93 whereas that against EBITDA is -3.14.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $14.97, while it has fallen to a 52-week low of $3.87. The 50-Day Moving Average of the stock is 4.6237, while the 200-Day Moving Average is calculated to be 6.6411.
For the past three months, ABCL has traded an average of 1.62M shares per day and 1.56M over the past ten days. A total of 286.85M shares are outstanding, with a floating share count of 198.02M. Insiders hold about 31.76% of the company’s shares, while institutions hold 39.90% stake in the company. Shares short for ABCL as of Oct 30, 2023 were 27.81M with a Short Ratio of 27.81M, compared to 25.72M on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.58% and a Short% of Float of 13.34%.
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of $-0.13 for the current quarter, with a high estimate of $-0.11 and a low estimate of $-0.2, while EPS last year was $-0.1. The consensus estimate for the next quarter is $-0.12, with high estimates of $-0.1 and low estimates of $-0.15.
Analysts are recommending an EPS of between $-0.43 and $-0.54 for the fiscal current year, implying an average EPS of $-0.47. EPS for the following year is $-0.63, with 7 analysts recommending between $-0.44 and $-0.86.
A total of 8 analysts believe the company’s revenue will be $9M this quarter.It ranges from a high estimate of $11.5M to a low estimate of $5.01M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $21.55M, an estimated decrease of -58.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $13.8M, an increase of 13.20% over than the figure of $-58.20% in the same quarter last year. There is a high estimate of $18.07M for the next quarter, whereas the lowest estimate is $11.3M.
A total of 8 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $45.2M, while the lowest revenue estimate was $33.86M, resulting in an average revenue estimate of $38.35M. In the same quarter a year ago, actual revenue was $485.42M, down -92.10% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $58.27M in the next fiscal year. The high estimate is $75.7M and the low estimate is $44.8M. The average revenue growth estimate for next year is up 51.90% from the average revenue estimate for this year.